FDA Vaccine Chief Leaving Post at End of April

The vaccine chief, Prasad, was responsible for confusion surrounding review of Moderna's mRNA flu vaccine, among other things.

The FDA’s vaccine chief, Vinay Prasad, is leaving his post at the end of April, according to the FDA commissioner. CIDRAP has the news.

Prasad was responsible for pulling the “review process from Moderna’s new mRNA flu vaccine, then [reversing] course, leading to confusion and public statements from Moderna’s CEO.”

He has also endured a public fight with UniQure, the “maker of a new gene therapy for Huntington’s disease. The company said last week [that] the FDA was demanding a new trial of its gene therapy, and that the trial would require some participants get a sham surgery, which they called unethical.”

Prasad also made “several chaotic moves at the FDA, at times announcing changes that make the FDA review process faster, and at other times issuing new warnings and onerous study requirements for some drugs and vaccines, which slowed the process.” His most notable change is the “FDA’s two-to-one policy, which says drugmakers are now required to show one well controlled clinical trial for new drug approvals instead of two.”

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates